Pfizer Recruits Chief Development Officer William Pao From Roche R&D Team

William Pao will oversee Pfizer's global product development organization, while Roche appointed Hans Clevers to take over from Pao as head of Roche’s pRED.

baton pass
New R&D leaders are joining Pfizer and Roche • Source: Alamy

Pfizer Inc. hired Roche Holding AG head of pharma Research and Early Development (pRED) William Pao as its chief development officer, triggering a leadership change within Roche's R&D leadership team. Both companies announced the respective transitions on 1 February, with Pao appointed to succeed Rod MacKenzie at Pfizer and Roche board member Johannes (Hans) Clevers tapped to succeed Pao.

Pao will oversee the global product development organization at Pfizer, responsible for the clinical development of Pfizer's innovative medicines pipeline...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

More from Scrip

Deal Watch: Lilly Teams With GPCR-Focused Superluminal In Cardiometabolic Disease

 
• By 

Plus deals involving Basilea/Venatorx, CorMedix/Melinta, SERB/Y-mAbs, XOMA/Lava, XOMA/Hillevax, MaxCyte/Adicet/Anocca and Bausch Health/DURECT.

Lilly Begins Rebalancing US/Ex-US Drug Costs By Raising Prices In Europe

 
• By 

Lilly said prices governments pay in developed countries, including those in Europe, need to increase to make US drug prices lower, rebalancing costs as CEO David Ricks recently advocated.

Schrödinger Drops CDC7 Inhibitor SGR-2921 After Two Patient Deaths

 

The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.